Synapse

← Hagop M. Kantarjian

Papers by Hagop M. Kantarjian

Page 10 · newest first

  1. Hematologic malignancies and Li–Fraumeni syndromeMolecular Case Studies · 2019
  2. How much of US health care spending provides direct care or benefit to patients?Cancer · 2019
  3. Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?Blood Cancer Journal · 2019
  4. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosisLeukemia & lymphoma/Leukemia and lymphoma · 2019
  5. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanismsNature Communications · 2019
  6. Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicinAmerican Journal of Hematology · 2019
  7. Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experienceJournal of Hematology & Oncology · 2019
  8. Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemiaTherapeutic Advances in Hematology · 2019
  9. Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemiaTherapeutic Advances in Hematology · 2019
  10. Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc‐concentration modellingBritish Journal of Clinical Pharmacology · 2018
  11. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3 ‐internal tandem duplication genotypesCancer · 2018
  12. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenibBlood · 2018
  13. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor–resistant chronic lymphocytic leukemia with disease progression and Richter transformationCancer · 2018
  14. The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemiaCancer · 2018
  15. A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)Blood · 2018
  16. A Clinical Study of Tomaralimab (OPN-305), a Toll-like Receptor 2 (TLR-2) Antibody, in Heavily Pre-Treated Transfusion Dependent Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received and Failed on Prior Hypomethylating Agent (HMA) TherapyBlood · 2018
  17. A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS)Blood · 2018
  18. A Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Blinatumomab As Frontline Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)Blood · 2018
  19. Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic SyndromeBlood · 2018
  20. Venetoclax in Combination with FLAG-IDA Chemotherapy (FLAG-V-I) for Fit, Relapsed/Refractory AML Patients: Interim Results of a Phase 1b/2 Dose Escalation and Expansion StudyBlood · 2018
  21. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II StudyCancer Discovery · 2018
  22. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American expertsAmerican Journal of Hematology · 2018
  23. PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic ChemotherapyCell stem cell · 2018
  24. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemiaBlood · 2018
  25. CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemiaHaematologica · 2018
  26. Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimensBlood Cancer Journal · 2018
  27. A phase II study of omacetaxine mepesuccinate for patients with higher‐risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agentsAmerican Journal of Hematology · 2018
  28. A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second‐ and third‐generation tyrosine kinase inhibitorsCancer Medicine · 2018
  29. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvageCancer · 2018
  30. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemiaCancer · 2018
  31. The opioid epidemic in the United States—Overview, origins, and potential solutionsCancer · 2018
  32. Toward the potential cure of leukemias in the next decadeCancer · 2018
  33. Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential valueCancer · 2018
  34. Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid LeukemiaFrontiers in Oncology · 2018
  35. Mutational landscape of myelodysplastic/myeloproliferative neoplasm–unclassifiableBlood · 2018
  36. The “American (cancer) patients first” plan to reduce drug prices—A critical assessmentAmerican Journal of Hematology · 2018
  37. Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDSLeukemia Research · 2018
  38. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosisBlood · 2018
  39. Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network · 2018
  40. Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemiaSHILAP Revista de lepidopterología · 2018
  41. P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse‐free survivalAmerican Journal of Hematology · 2018
  42. High-throughput single-cell DNA sequencing of acute myeloid leukemia tumors with droplet microfluidicsGenome Research · 2018
  43. Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categoriesBlood Advances · 2018
  44. Prognosis of patients with intermediate risk IPSS‐R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS‐RAmerican Journal of Hematology · 2018
  45. Sorafenib Combined with 5‐azacytidine in Older Patients with Untreated FLT3‐ITD Mutated Acute Myeloid LeukemiaAmerican Journal of Hematology · 2018
  46. Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypesNature Communications · 2018
  47. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AMLBlood · 2018
  48. Durable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AMLNew England Journal of Medicine · 2018
  49. Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemiaHaematologica · 2018
  50. Long-term survival of adults with B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) after treatment with blinatumomab and subsequent allogeneic hematopoietic stem cell transplantation (HSCT).Journal of Clinical Oncology · 2018